<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03444844</url>
  </required_header>
  <id_info>
    <org_study_id>IU-1711061247</org_study_id>
    <nct_id>NCT03444844</nct_id>
  </id_info>
  <brief_title>Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer With Biochemical Recurrence</brief_title>
  <official_title>Biodistribution and Dosimetry of the Investigational PET Agent Ga-68 P16-093 in Prostate Cancer Patients With Biochemical Recurrence Undergoing Clinical Ga-68 PSMA-11 PET/CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Five Eleven Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Five Eleven Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Whole body biodistribution and dosimetry with preliminary comparison to PSMA-11 in prostate
      cancer patients with biochemical recurrence
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Organ uptake of Ga-68 P16-093 for dosimetry calculation</measure>
    <time_frame>0 to approximately 150 min post injection</time_frame>
    <description>Total organ uptake of Ga-68 P16-093 as a function of time for major organs defined by whole body PET/CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specificity of Ga-68 P16-093</measure>
    <time_frame>approximately 60 - 120 min post injection</time_frame>
    <description>Qualitative comparison of detection local versus distant metastases compared to clinical PSMA-11 results</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Prostate Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Ga-68 P16-093 PET/CT scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV injection of 2 - 6 mCi of Ga-68 P16-093 followed by PET/CT scanning for approximately 150 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ga-68 P16-093 PET/CT scan</intervention_name>
    <description>IV injection followed by PET/CT scanning</description>
    <arm_group_label>Ga-68 P16-093 PET/CT scan</arm_group_label>
    <other_name>PSMA-93</other_name>
    <other_name>HBED-CC-PHENOXY-PSMA</other_name>
    <other_name>PSMA-093</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing a clinical Ga-68 PSMA-11 PET/CT scan under IND 131806 in the
             proceeding 60 days

          -  Informed consent and agreement to allow investigator to access the results of clinical
             Ga-68 PSMA-11 scan for comparison to findings wth Ga-68 P16-093.

        Exclusion Criteria:

          -  inability to give informed consent

          -  Initiation of treatment (surgery, radiation therapy, or modified drug therapy) for the
             patient's prostate cancer in the time interval between the clinical Ga-68 PSMA-11
             PET/CT and the Ga-68 P16-093 PET/CT.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Green, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hayley Trussell, BSN, RN</last_name>
    <phone>317-962-5201</phone>
    <email>hktrusse@iupui.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Goodman Hall, Indiana Institute for Biomedical Imaging Sciences, Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Green, Ph.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

